Ending Discrimination Against People with Mental and Substance Use Disorders


Book Description

Estimates indicate that as many as 1 in 4 Americans will experience a mental health problem or will misuse alcohol or drugs in their lifetimes. These disorders are among the most highly stigmatized health conditions in the United States, and they remain barriers to full participation in society in areas as basic as education, housing, and employment. Improving the lives of people with mental health and substance abuse disorders has been a priority in the United States for more than 50 years. The Community Mental Health Act of 1963 is considered a major turning point in America's efforts to improve behavioral healthcare. It ushered in an era of optimism and hope and laid the groundwork for the consumer movement and new models of recovery. The consumer movement gave voice to people with mental and substance use disorders and brought their perspectives and experience into national discussions about mental health. However over the same 50-year period, positive change in American public attitudes and beliefs about mental and substance use disorders has lagged behind these advances. Stigma is a complex social phenomenon based on a relationship between an attribute and a stereotype that assigns undesirable labels, qualities, and behaviors to a person with that attribute. Labeled individuals are then socially devalued, which leads to inequality and discrimination. This report contributes to national efforts to understand and change attitudes, beliefs and behaviors that can lead to stigma and discrimination. Changing stigma in a lasting way will require coordinated efforts, which are based on the best possible evidence, supported at the national level with multiyear funding, and planned and implemented by an effective coalition of representative stakeholders. Ending Discrimination Against People with Mental and Substance Use Disorders: The Evidence for Stigma Change explores stigma and discrimination faced by individuals with mental or substance use disorders and recommends effective strategies for reducing stigma and encouraging people to seek treatment and other supportive services. It offers a set of conclusions and recommendations about successful stigma change strategies and the research needed to inform and evaluate these efforts in the United States.




Methods of Behavior Analysis in Neuroscience


Book Description

Using the most well-studied behavioral analyses of animal subjects to promote a better understanding of the effects of disease and the effects of new therapeutic treatments on human cognition, Methods of Behavior Analysis in Neuroscience provides a reference manual for molecular and cellular research scientists in both academia and the pharmaceutic




Drug Discrimination


Book Description

Drug discrimination: a practical guide to its contributions to the invention of new chemical entities and evaluations of new or known pharmacological agents Drug discrimination can be described as a "drug detection" procedure that uses a pharmacologically active agent as the subjective stimulus. Although the procedure does require some effort to implement, it can be an extremely important tool for understanding drug action. Whereas medicinal chemists should come to learn the types of information that drug discrimination studies can offer, pharmacologists and psychologists might come to realize how medicinal chemists can apply the types of information that the paradigm routinely provides. Drug Discrimination: Applications to Medicinal Chemistry and Drug Studies provides in-depth analyses of the nature and use of drugs as discriminative stimuli and bridges some of the numerous gaps between medicinal chemistry, pharmacology, and psychology. Stressing the practical aspects of drug discrimination, including types of procedures, study design, data, and interpretation, the book details the advantages and limitations of drug discrimination studies versus other pharmacologic evaluations. Practical information from leading researchers in the field addresses specific topics and techniques that are of interest in drug discovery, evaluation, and development. A groundbreaking new guide to the applications of drug discrimination studies for medicinal chemistry and neuroscience, Drug Discrimination is essential for any scientist, researcher, or student whose interests involve the design, development, and/or action of drugs acting at the level of the central nervous system.




Transduction Mechanisms of Drug Stimuli


Book Description

In this book the latest data available on transduction mechanisms of drug stimuli are presented. A common theme underlying the chapter in this volume is the recognition that drugs can act as stimuli, in much the same manner as external events do. Accordingly, the papers focus on the mechanisms by which these stimuli are transduced at different levels of analysis, such as the behavioral, pharmacological, and molecular levels. Some chapters discuss the mechanisms of transduction of the discriminative effects of several important classes of drugs, while others deal with the methods and research strategies by which these mechanisms can be analyzed. Collectively, the papers in this volume reflect the current status of knowledge in the rapidly expanding field of behavioral pharmacology.




The Behavioral Neuroscience of Drug Discrimination


Book Description

The goal for this volume is to provide an up-to-date review of the discriminative stimulus properties of major psychoactive drug classes with an emphasis on how this paradigm enhances our understanding of these drugs and how these findings translate from animals to humans. The drug discrimination paradigm applies to both drugs of abuse and drugs for treating mental illnesses, and research from these studies has provided immense translational value for learning about the mechanisms responsible for drug effects in humans.




Medications for Opioid Use Disorder Save Lives


Book Description

The opioid crisis in the United States has come about because of excessive use of these drugs for both legal and illicit purposes and unprecedented levels of consequent opioid use disorder (OUD). More than 2 million people in the United States are estimated to have OUD, which is caused by prolonged use of prescription opioids, heroin, or other illicit opioids. OUD is a life-threatening condition associated with a 20-fold greater risk of early death due to overdose, infectious diseases, trauma, and suicide. Mortality related to OUD continues to escalate as this public health crisis gathers momentum across the country, with opioid overdoses killing more than 47,000 people in 2017 in the United States. Efforts to date have made no real headway in stemming this crisis, in large part because tools that already existâ€"like evidence-based medicationsâ€"are not being deployed to maximum impact. To support the dissemination of accurate patient-focused information about treatments for addiction, and to help provide scientific solutions to the current opioid crisis, this report studies the evidence base on medication assisted treatment (MAT) for OUD. It examines available evidence on the range of parameters and circumstances in which MAT can be effectively delivered and identifies additional research needed.




Methods of Assessing the Reinforcing Properties of Abused Drugs


Book Description

Methods of Assessing the Reinforcing Properties of Abused Drugs presents a synopsis of the preclinical procedures used to assess drug reinforcement. Researchers using one technique are provided with an overview of the other available methods, and clinicians who wish to evaluate drug abuse research reports can gain the necessary background from this volume. Although emphasis is placed on the methodological aspects of assessing drug reinforcement, some of the scientific conclusions derived from using these techniques are also presented. This edited collection offers a lasting framework for interpreting the results of current experimental findings.




Stimulus Properties of Drugs


Book Description

Behavioral pharmacology represents a relatively recent scientific enterprise, the development of which can be followed by plotting the publication of major conceptual papers, review articles, and books. Dews (1955), Sidman (1955), and Brady (1956) published some of the first methodologically significant papers, changing the way both psychologists and pharmacologists viewed the analysis of the behavioral actions of drugs. Dews and Morse (1961), Cook and Kelleher (1963), Gollub and Brady (1965), and Weiss and Laties (1969) kept the field abreast of major developments in the study of behavioral mechanisms of drug action. In 1968, the first textbook in the field was published (Thompson and Schuster), followed by a book of readings covering the preceding 15 years of the field (Thompson, Pickens, and Meisch, 1970). The first attempt to outline a set of generalizations concerning behavioral mechanisms of drug actions was puhlished in 1968 by Kelleher and Morse. As behavioral pharmacology developed, it became clear that demonstrations that drugs affect hehavior were relatively uninteresting. It was the mechanisms by which these effects are hrought about that was of concern. While other aspects of pharmacology have been concerned with biochemical, physiological, and in some cases biophysical accounts of drug actions, behavioral pharmacology has dealt with behavioral mechanisms . . . that is, "any verifiable description of a drug's effects which can he shown to uniquely covary with a specific measured 'response'. Generally, this relation can be subsumed under some more general set of relations or principles" (Thompson, Pickens, and Meisch, 1970, p. I).




Unequal under Law


Book Description

Race is clearly a factor in government efforts to control dangerous drugs, but the precise ways that race affects drug laws remain difficult to pinpoint. Illuminating this elusive relationship, Unequal under Law lays out how decades of both manifest and latent racism helped shape a punitive U.S. drug policy whose onerous impact on racial minorities has been willfully ignored by Congress and the courts. Doris Marie Provine’s engaging analysis traces the history of race in anti-drug efforts from the temperance movement of the early 1900s to the crack scare of the late twentieth century, showing how campaigns to criminalize drug use have always conjured images of feared minorities. Explaining how alarm over a threatening black drug trade fueled support in the 1980s for a mandatory minimum sentencing scheme of unprecedented severity, Provine contends that while our drug laws may no longer be racist by design, they remain racist in design. Moreover, their racial origins have long been ignored by every branch of government. This dangerous denial threatens our constitutional guarantee of equal protection of law and mutes a much-needed national discussion about institutionalized racism—a discussion that Unequal under Law promises to initiate.




Drugs Are Not the Devil's Tools - Vol.2, Black & White Edition: How Discrimination and Greed Created a Dysfunctional Drug Policy and How It Can Be Fix


Book Description

"Drugs are NOT the Devil’s Tools is a[n] ... examination into the origin of United States drug laws. Dr. David Bearman shows how, through intertwining motives of discrimination and greed, often under the guise of morality, they have created a drug policy that is completely dysfunctional. As he points out, our drug laws have been very effective in further marginalizing discriminated-against groups and a total failure in every other respect. In his new book, Dr. Bearman shows that there has rarely been a civilization in the history of mankind that has not used some form of man-altering substance. He also demonstrates that the very real medical properties of cannabis were recognized thousands of years ago, as were the medicinal uses of opium, coca, alcohol and spices..."--Back cover.